StoxIpca Laboratories vs Emcure Pharmaceuticals: share price & financials comparison
NSE: IPCALAB vs EMCURE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Ipca Laboratories vs Emcure Pharmaceuticals at a glance
Ipca Laboratories (IPCALAB) has a market capitalisation of ₹47,797 Cr, against ₹44,804 Cr for Emcure Pharmaceuticals (EMCURE). Over the past year Emcure Pharmaceuticals has returned +78.3%, compared with +45.5% for Ipca Laboratories. On valuation, Ipca Laboratories trades at a lower P/E of 34.1 versus 41.0. Emcure Pharmaceuticals earns a higher return on equity (20.5% vs 16.2%). Ipca Laboratories comes out ahead on size, valuation, profitability and financial health. Emcure Pharmaceuticals comes out ahead on growth, momentum and technicals. Across the scored metrics below, Ipca Laboratories leads on 6 and Emcure Pharmaceuticals on 8. On StoxGud's 10-point checklist, Ipca Laboratories scores 8/10 and Emcure Pharmaceuticals scores 9/10.
| Metric | Ipca Laboratories | Emcure Pharmaceuticals |
|---|---|---|
| Size | ||
| Market cap | ₹47,797 Cr | ₹44,804 Cr |
| Revenue (latest FY) | ₹9,646 Cr | ₹9,204 Cr |
| Net profit (latest FY) | ₹1,141 Cr | ₹924 Cr |
| Valuation | ||
| P/E | 34.1 | 41.0 |
| P/B | 5.51 | 8.38 |
| Dividend yield | 0.11% | 0.13% |
| Profitability | ||
| Return on equity | 16.2% | 20.5% |
| Net profit margin | 13.4% | 10.7% |
| Operating margin | 22.5% | 20.4% |
| Growth | ||
| Revenue growth (YoY) | +13.8% | +24.3% |
| Net profit growth (YoY) | +32.8% | +33.7% |
| Revenue CAGR (multi-year) | +12.2% | — |
| Financial health | ||
| Debt to equity | 0.07 | 0.27 |
| Momentum | ||
| 1-month return | -1.8% | +26.4% |
| 1-year return | +45.5% | +78.3% |
| 3-year CAGR | +21.3% | — |
| 5-year CAGR | +11.4% | — |
| 10-year CAGR | +21.4% | — |
| Distance from 52W high | -6.2% | +0.0% |
| Technicals | ||
| RSI (14) | 38 | 94 |
| Price vs 200-day avg | +11.2% | +34.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Ipca Laboratories | Emcure Pharmaceuticals |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 8/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Ipca Laboratories or Emcure Pharmaceuticals?
Ipca Laboratories has a market cap of ₹47,797 Cr and Emcure Pharmaceuticals has a market cap of ₹44,804 Cr as of 13 Nov 2026.
Which has a lower P/E, Ipca Laboratories or Emcure Pharmaceuticals?
Ipca Laboratories has the lower P/E: Ipca Laboratories trades at 34.1 and Emcure Pharmaceuticals at 41.0.
Which gave better returns in the last year, Ipca Laboratories or Emcure Pharmaceuticals?
Emcure Pharmaceuticals did better: Ipca Laboratories returned +45.5% and Emcure Pharmaceuticals returned +78.3% over one year.
What is the difference between Ipca Laboratories and Emcure Pharmaceuticals?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹47,797 Cr vs ₹44,804 Cr). In the latest financial year Ipca Laboratories reported revenue of ₹9,646 Cr and Emcure Pharmaceuticals ₹9,204 Cr. Operating margin is 22.5% for Ipca Laboratories and 20.4% for Emcure Pharmaceuticals. Debt to equity is 0.07 for Ipca Laboratories and 0.27 for Emcure Pharmaceuticals.
Which is better, Ipca Laboratories or Emcure Pharmaceuticals?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Ipca Laboratories leads on 6 and Emcure Pharmaceuticals on 8. Ipca Laboratories is ahead on size, valuation, profitability and financial health. Emcure Pharmaceuticals is ahead on growth, momentum and technicals. On StoxGud's rules-based checklist Ipca Laboratories scores 8/10 and Emcure Pharmaceuticals scores 9/10. This is information, not advice: consult a SEBI-registered adviser before investing.